Merck

News mentioning Merck · Wikidata · RSS

Top stories

Latest

1. Merck stops making Recarbrio, highlighting tricky landscape for new antibioticshealio.com · 2026-10-02 19:39 UTC · story
2. Merck pulls antibiotic for multidrug-resistant infections from US marketumn.edu · 2026-09-30 04:52 UTC · 1 more reports
3. Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Shortmedicaldaily.com · 2026-09-30 04:17 UTC · story
4. Merck highlights new technology to monitor calf behaviorbrownfieldagnews.com · 2026-09-29 20:41 UTC · story
5. Merck buys a pre-clinical oral drug under research in China for $400 millionnews.baidu.com · 2026-09-29 17:48 UTC · story
6. Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last Yearaol.com · 2026-09-29 15:27 UTC · story
7. Factset's latest survey: Merck's target price raised to 160, up about 3.23%news.cnyes.com · 2026-09-29 12:15 UTC · story
   
8. Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & PfizerGlobeNewswire — all · 2026-09-29 09:22 UTC · story
9. AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest growsscmp.com · 2026-09-29 09:00 UTC · story
   
10. Merck (MRK) Withdrew a Cancer Filing. Is the Drug's Promise Still Intact?insidermonkey.com · 2026-09-29 03:15 UTC · story
11. STAT+: Merck discontinues a crucial antibiotic despite concerns over superbug resistancestatnews.com · 2026-09-28 20:45 UTC · story
    
12. Merck, Daiichi end plans to seek speedy approval of lung cancer ADCbiopharmadive.com · 2026-09-28 17:40 UTC · story
13. Merck pens $2.1B deal with China's SciBrunch to chase KRAS G12Dfiercebiotech.com · 2026-09-28 15:23 UTC · story
14. STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and morestatnews.com · 2026-09-28 13:06 UTC · story
    
15. Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealfiercebiotech.com · 2026-09-28 10:22 UTC · story
16. Global Cell Line Generation Market Outlook, 2026-2032 - AI, CRISPR and Automation Fuel 10.86% CAGR, Driving the Market to USD 2.67 Billion as Thermo Fisher Scientific, Lonza, Merck and WuXi Biologics Advance InnovationGlobeNewswire — all · 2026-09-28 09:03 UTC · story
17. Daiichi, Merck Withdraw U.S. Filing For Lung Cancer Drug Ifinatamab Deruxtecarttnews.com · 2026-09-28 08:51 UTC · story
18. Merck and Daiichi Sankyo withdraw FDA approval application for new lung cancer drug 'Ifinatamab Deruxtecan'cdn.pharmnews.com · 2026-09-28 00:11 UTC · story